SK166695A3 - Mgdf polypeptide for stimulating growth and megakaryocyte differentiation - Google Patents

Mgdf polypeptide for stimulating growth and megakaryocyte differentiation Download PDF

Info

Publication number
SK166695A3
SK166695A3 SK1666-95A SK166695A SK166695A3 SK 166695 A3 SK166695 A3 SK 166695A3 SK 166695 A SK166695 A SK 166695A SK 166695 A3 SK166695 A3 SK 166695A3
Authority
SK
Slovakia
Prior art keywords
mgdf
polypeptide
mpl
soluble polymer
water
Prior art date
Application number
SK1666-95A
Other languages
English (en)
Slovak (sk)
Inventor
Timothy D Bartley
Jakob M Bogenberger
Robert A Bosselman
Pamela Hunt
Olaf B Kinstler
Babru B Samal
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/321,488 external-priority patent/US5795569A/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SK166695A3 publication Critical patent/SK166695A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SK1666-95A 1994-03-31 1995-03-30 Mgdf polypeptide for stimulating growth and megakaryocyte differentiation SK166695A3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22176894A 1994-03-31 1994-03-31
US25262894A 1994-05-31 1994-05-31
US08/321,488 US5795569A (en) 1994-03-31 1994-10-12 Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US34778094A 1994-11-30 1994-11-30
PCT/US1995/003776 WO1995026746A1 (en) 1994-03-31 1995-03-30 Compositions and methods for stimulating megakaryocyte growth and differentiation

Publications (1)

Publication Number Publication Date
SK166695A3 true SK166695A3 (en) 1997-02-05

Family

ID=27499246

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1666-95A SK166695A3 (en) 1994-03-31 1995-03-30 Mgdf polypeptide for stimulating growth and megakaryocyte differentiation

Country Status (32)

Country Link
US (1) US5766581A (cs)
EP (3) EP0675201A1 (cs)
JP (2) JP2996415B2 (cs)
KR (2) KR100203824B1 (cs)
CN (2) CN1229385C (cs)
AT (1) ATE169335T1 (cs)
AU (1) AU691606B2 (cs)
BG (1) BG62685B1 (cs)
BR (1) BR9506017A (cs)
CA (1) CA2167090C (cs)
CZ (2) CZ288926B6 (cs)
DE (1) DE69503849T2 (cs)
DK (1) DK0690127T3 (cs)
EE (1) EE9600121A (cs)
ES (1) ES2119250T3 (cs)
FI (1) FI960136L (cs)
GE (1) GEP20002180B (cs)
GR (1) GR3027593T3 (cs)
HK (1) HK1041275B (cs)
HU (1) HU218893B (cs)
IL (1) IL113206A0 (cs)
LV (2) LV11783B (cs)
MY (1) MY113048A (cs)
NO (1) NO960111L (cs)
NZ (1) NZ283863A (cs)
PL (1) PL182567B1 (cs)
RO (1) RO115788B1 (cs)
SI (1) SI0690127T1 (cs)
SK (1) SK166695A3 (cs)
TW (3) TW565568B (cs)
WO (1) WO1995026746A1 (cs)
YU (1) YU20095A (cs)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996017062A1 (en) * 1994-11-30 1996-06-06 Zymogenetics, Inc. Low molecular weight thrombopoietin
US5986049A (en) * 1994-12-30 1999-11-16 Zymogenetics, Inc. Purified thrombopoietin and method of making it
TW387940B (en) * 1995-01-17 2000-04-21 Kirin Brewery Anti-tpo monodonal antibody
AU4658596A (en) 1995-02-03 1996-08-21 G.D. Searle & Co. Novel c-mpl ligands
AU691410B2 (en) * 1995-02-15 1998-05-14 Amgen, Inc. MPL ligand analogs
US5696250A (en) * 1995-02-15 1997-12-09 Amgen Inc. DNA encoding megakaryocyte growth and development factor analogs
US5989538A (en) * 1995-02-15 1999-11-23 Amgen Inc. Mpl ligand analogs
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
PT885242E (pt) 1995-06-07 2008-06-18 Glaxo Group Ltd Péptidos e compostos que se ligam a um receptor de trombopoietina
TW497972B (en) * 1995-06-08 2002-08-11 Kirin Brewery Stable thrombopoietin (TPO)-containing lyophilized compositions
US6066318A (en) 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
WO1997012978A1 (en) * 1995-10-05 1997-04-10 G.D. Searle & Co. NOVEL c-mpl RECEPTOR AGONISTS
US5879673A (en) * 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
CN1142940C (zh) * 1996-10-04 2004-03-24 安姆根有限公司 含有mpl配体的药物组合物
US5914251A (en) * 1996-10-22 1999-06-22 Amgen Inc. Nucleic acid molecules encoding placental-derived growth factors
AU2006201129B2 (en) * 1997-05-21 2008-03-13 Genentech, Inc. Novel administration of thrombopoietin
JP4562815B2 (ja) * 1997-05-21 2010-10-13 ジェネンテック， インコーポレイテッド トロンボポエチンの新規な投与
SI1075281T1 (en) * 1998-04-28 2005-02-28 Applied Research Systems Ars Holding N.V. Polyol-ifn-beta conjugates
US20030228666A1 (en) 1998-06-30 2003-12-11 Daewoong Pharmaceutical Co., Ltd. Novel human thrombopoietin mutein
PT2319928E (pt) 1998-10-23 2013-06-28 Kirin Amgen Inc Péptidos diméricos de trombopoietina que simulam a ligação ao receptor mpl e têm actividade trombopoiética
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000057891A1 (en) 1999-03-30 2000-10-05 Trustees Of Boston University Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
AU2001280096B2 (en) 2000-08-11 2007-03-22 Kyowa Kirin Co., Ltd. Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAs encoding the same
WO2002015926A1 (fr) * 2000-08-24 2002-02-28 Kirin Beer Kabushiki Kaisha Compositions medicinales contenant des ligands c-mpl, destinees a l'augmentation des plaquettes et des erythrocytes
UY26317A1 (es) * 2000-08-30 2000-10-31 Alfonso Cayota Carlos Pritsch Sistema de produccion de trombopoyetina humana por celulas de mamiferos en cultivo
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
WO2004014938A2 (en) * 2002-08-09 2004-02-19 Xencor Thrombopoiesis-stimulating proteins having reduced immunogenicity
EA010759B1 (ru) 2002-09-18 2008-10-30 Орто-Макнейл Фармасьютикал, Инк. Способы увеличения продукции тромбоцитов и гематопоэтических стволовых клеток
WO2004060299A2 (en) * 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
EP1628618A4 (en) * 2002-12-26 2009-09-09 Mountain View Pharmaceuticals POLYMER CONJUGATES OF CYTOKINES, CHEMOKINS, GROWTH FACTORS, POLYPEPTIDE HORMONES AND ANTAGONISTS THEREOF WITH PRESERVED RECEPTOR BINDING ACTIVITY
US7256206B2 (en) * 2003-02-11 2007-08-14 Irm Llc Bicyclic compounds and compositions
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CN1942588B (zh) 2003-03-05 2013-06-12 海洋酶公司 可溶性透明质酸酶糖蛋白(sHASEGP)、制备它们的方法、它们的用途和包含它们的药物组合物
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP1610825A2 (en) * 2003-03-31 2006-01-04 Xencor, Inc. Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
EA009286B1 (ru) 2003-08-28 2007-12-28 Орто-Макнейл Фармасьютикал, Инк. Пептиды и соединения, которые связываются с рецептором
WO2005035564A2 (en) 2003-10-10 2005-04-21 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
PL1699915T3 (pl) 2003-12-30 2010-11-30 Augustinus Bader Zastosowanie erytropoetyny do regeneracji tkanki wątrobowej
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
WO2005123113A2 (en) * 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
JP2008505928A (ja) 2004-07-08 2008-02-28 アムジェン　インコーポレーテッド 治療用ペプチド
MX2007000568A (es) * 2004-07-16 2007-03-30 Nektar Therapeutics Al Corp Conjugados de una fraccion gm-csf y un polimero.
CA2580796C (en) 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
EP1805155B1 (en) 2004-10-25 2010-11-03 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007102946A2 (en) 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
US8318153B2 (en) * 2006-06-29 2012-11-27 Nalin David R Method of medically treating an individual
JP5591691B2 (ja) 2007-05-22 2014-09-17 アムジエン・インコーポレーテツド 生物活性を有する融合タンパク質を作製するための組成物及び方法
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
SG187427A1 (en) 2008-04-14 2013-02-28 Halozyme Inc Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
ES2724588T3 (es) 2008-12-09 2019-09-12 Halozyme Inc Polipéptidos de PH20 soluble extendida y usos de los mismos
WO2010074831A1 (en) 2008-12-16 2010-07-01 Dow Corning Corporation Preparation of siloxanes
KR101040396B1 (ko) 2009-01-20 2011-06-09 한올바이오파마주식회사 변형된 인간 트롬보포이에틴 폴리펩타이드 절편 및 그의 제조방법
US8680150B2 (en) * 2009-05-28 2014-03-25 Ligand Pharmaceuticals, Inc. Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
EP3127427B1 (en) 2009-05-29 2020-01-08 Novartis Ag Methods of administration of thrombopoietin agonist compounds
CA2774053C (en) 2009-09-17 2015-04-28 Baxter Healthcare, S.A. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
EP2595624B1 (en) 2010-07-20 2018-01-31 Halozyme, Inc. Methods of treatment or prevention of the adverse side-effects associated with administration of an anti-hyaluronan agent
JP2014510045A (ja) 2011-02-08 2014-04-24 ハロザイム インコーポレイテッド ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
JP5890516B2 (ja) 2011-06-17 2016-03-22 ハロザイム インコーポレイテッド ヒアルロナン分解酵素を用いる連続的皮下インスリン注入方法
WO2013040501A1 (en) 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
EA030440B1 (ru) 2011-10-24 2018-08-31 Галозим, Инк. Сопровождающая диагностика для терапии антигиалуронановым агентом и способы ее применения
SMT201900630T1 (it) 2011-12-30 2020-01-14 Halozyme Inc Varianti di polipeptide ph20, loro formulazioni e loro usi
KR101809858B1 (ko) 2012-04-04 2017-12-15 할로자임, 아이엔씨 항-히알루로난 제제 및 종양-표적 탁산을 이용한 병용 치료
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
EP3186281B1 (en) 2014-08-28 2019-04-10 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
CA3203273A1 (en) 2014-10-14 2016-04-21 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CN111107870A (zh) 2017-06-22 2020-05-05 催化剂生物科学公司 经修饰的膜型丝氨酸蛋白酶1（mtsp-1）多肽及其使用方法
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
CN113661239A (zh) 2018-12-28 2021-11-16 催化剂生物科学公司 经修饰的尿激酶型纤溶酶原激活物多肽和使用方法
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4894440A (en) * 1986-09-17 1990-01-16 Massachusetts Institute Of Technology Method of isolating megakaryocyte stimulatory factor
ZA887773B (en) * 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
IL90719A0 (en) * 1988-06-28 1990-01-18 Yissum Res Dev Co Novel nuclei acids and polypeptides encoded thereby
US5128449A (en) * 1988-07-05 1992-07-07 The University Of Tennessee Research Corporation Polypeptide and a method for its production
WO1990003397A1 (en) * 1988-09-21 1990-04-05 Meiji Seika Kaisha, Ltd. Novel megakaryocytic colony stimulating factor and process for its preparation
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
DE68925966T2 (de) * 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5087448A (en) * 1989-02-02 1992-02-11 The Board Of Regents Of The University Of Oklahoma Enhancing growth of megakaryocytes in mammals using interleuking 6
US5032396A (en) * 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production
WO1990012108A1 (en) * 1989-04-03 1990-10-18 Genetics Institute, Inc. Megakaryocyte growth promoting activity
US5260417A (en) * 1989-04-03 1993-11-09 Genetics Institute, Inc. Megakaryocyte growth promoting activity protein
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US6433142B1 (en) * 1989-08-08 2002-08-13 Genetics Institute, Llc Megakaryocyte stimulating factors
EP0732401A3 (en) * 1989-08-08 1997-05-14 Genetics Inst Megacaryocyte stimulating factor (meg-CSF)
US5215895A (en) * 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
EP0672684A1 (en) * 1990-05-31 1995-09-20 Meija Seika Kabushiki Kaisha, Ltd. Novel megakaryocyte colony stimulating factor and production thereof
KR930701475A (ko) * 1990-07-02 1993-06-11 원본미기재 사람의 거핵구-집락 촉진 인자(hMeg-CSF) 및 그것의 생산방법
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
CA2069879A1 (en) * 1990-10-05 1992-04-06 George Tidmarsh Megakaryocyte and platelet growth, production and composition
AU8868891A (en) * 1990-10-12 1992-05-20 Amgen, Inc. Megakaryocyte maturation factors
WO1992007074A1 (fr) * 1990-10-19 1992-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptide de la famille d'un recepteur de facteur de croissance, application au diagnostic et a la therapie des maladies myeloproliferatives
WO1992012177A1 (fr) * 1990-12-28 1992-07-23 Asahi Kasei Kogyo Kabushiki Kaisha Nouvel amplificateur de megakaryocyte et sa production
JP3283288B2 (ja) * 1991-03-08 2002-05-20 電気化学工業株式会社 生理活性ペプチド製剤
JPH04295500A (ja) * 1991-03-26 1992-10-20 Asahi Chem Ind Co Ltd 新規な巨核球増幅因子とその製法
AU2296992A (en) * 1991-06-28 1993-01-25 New England Deaconess Hospital A differentiated megakaryocyte line producing novel megakaryocyte differentiation factors
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
NZ244778A (en) * 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
JP3328341B2 (ja) * 1991-12-27 2002-09-24 中外製薬株式会社 新規な巨核球増幅因子
WO1993016106A1 (en) * 1992-02-07 1993-08-19 Asahi Kasei Kogyo Kabushiki Kaisha Novel megakaryocyte amplifier and production thereof
AU4190893A (en) * 1992-07-17 1994-01-20 Suntory Limited Megakaryocyte differentiation factor
GB2285446B (en) * 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
NZ281482A (en) * 1994-02-14 2000-09-29 Univ Washington The stimulation of erythropoiesis using thrombopoietin and erythropoietin
CN1148408A (zh) * 1994-02-14 1997-04-23 津莫吉尼蒂克斯公司 血细胞生成蛋白及其制造材料和方法
EP0668352A1 (en) * 1994-02-14 1995-08-23 Kirin Brewery Company, Ltd. Protein having TPO activity
US5547931A (en) * 1994-02-23 1996-08-20 Immtech International Inc. Methods of stimulatory thrombocytopoiesis using modified C-reactive protein
US5571686A (en) * 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets

Also Published As

Publication number Publication date
CZ288890B6 (cs) 2001-09-12
CN1322759A (zh) 2001-11-21
HU9600059D0 (en) 1996-03-28
GEP20002180B (en) 2000-07-25
JPH10510980A (ja) 1998-10-27
JP3485842B2 (ja) 2004-01-13
CA2167090A1 (en) 1995-10-12
CA2167090C (en) 2002-05-14
KR100303810B1 (ko) 2001-12-01
LV12275A (lv) 1999-05-20
BR9506017A (pt) 1997-10-14
EP0675201A1 (en) 1995-10-04
TW496870B (en) 2002-08-01
IL113206A0 (en) 1995-06-29
DE69503849T2 (de) 1999-04-01
NO960111L (no) 1996-09-24
CN1229385C (zh) 2005-11-30
TW565568B (en) 2003-12-11
HK1004231A1 (en) 1998-11-20
US5766581A (en) 1998-06-16
FI960136A0 (fi) 1996-01-11
HK1041275A1 (en) 2002-07-05
HU218893B (hu) 2000-12-28
SI0690127T1 (en) 1998-12-31
FI960136A7 (fi) 1996-03-11
CZ350595A3 (en) 1997-01-15
LV11783B (en) 1997-12-20
FI960136L (fi) 1996-03-11
NZ283863A (en) 1997-12-19
PL182567B1 (pl) 2002-01-31
AU691606B2 (en) 1998-05-21
NO960111D0 (no) 1996-01-10
ES2119250T3 (es) 1998-10-01
DE69503849D1 (de) 1998-09-10
YU20095A (sh) 1998-08-14
JP2000103799A (ja) 2000-04-11
EP0755263A1 (en) 1997-01-29
EP0690127A1 (en) 1996-01-03
BG62685B1 (bg) 2000-05-31
KR100203824B1 (ko) 1999-06-15
DK0690127T3 (da) 1999-05-03
HUT74257A (en) 1996-11-28
LV12275B (en) 1999-08-20
PL312577A1 (en) 1996-04-29
JP2996415B2 (ja) 1999-12-27
AU2230895A (en) 1995-10-23
BG100625A (bg) 1997-04-30
TW414799B (en) 2000-12-11
ATE169335T1 (de) 1998-08-15
MY113048A (en) 2001-11-30
MX9600206A (es) 1998-11-30
EP0690127B1 (en) 1998-08-05
CZ288926B6 (cs) 2001-09-12
LV11783A (lv) 1997-06-20
RO115788B1 (ro) 2000-06-30
EE9600121A (et) 1997-04-15
HK1041275B (zh) 2006-07-28
WO1995026746A1 (en) 1995-10-12
GR3027593T3 (en) 1998-11-30
EP0755263A4 (en) 2005-02-09
CN1103782C (zh) 2003-03-26
CN1137757A (zh) 1996-12-11

Similar Documents

Publication Publication Date Title
EP0690127B1 (en) Compositions and methods for stimulating megakaryocyte growth and differentiation
US5795569A (en) Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
CA2178752C (en) N-terminally chemically modified protein compositions and methods
CA2209298C (en) Mpl ligand analogs
AU727978B2 (en) MPL ligand analogs
RU2158603C2 (ru) Способы и препараты для стимулирования роста и дифференцировки мегакариоцитов
HK1004231B (en) Compositions and methods for stimulating megakaryocyte growth and differentiation
HK1008340A (en) Compositions and methods for stimulating megakaryocyte growth and differentiation
MXPA96000206A (en) Compositions and methods to stimulate the growth and differentiation of the megacarioci
AU2128502A (en) N-terminally chemically modified protein compositions and methods